Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2020-10-22 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Prospectus Supplement
Report Publication Announcement Classification · 1% confidence The document is a filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key phrase is "Attached hereto is a report on *Prospectus Supplement*" followed by a PDF filename. This indicates the document itself is an announcement about the publication of a Prospectus Supplement, rather than the Prospectus Supplement itself. Since 'Prospectus Supplement' is a financing/capital-related document, and this is merely the announcement of its release, it fits best under Capital/Financing Update (CAP) if the supplement is the primary focus, or Report Publication Announcement (RPA) if the focus is the act of publishing. Given the specific nature of a Prospectus Supplement (related to offering securities), CAP is a strong candidate, but RPA is the most accurate classification based on the 'MENU VS MEAL' rule, as this is an announcement stating a report is attached/published. However, looking at the definitions, 'CAP' covers fundraising/financing activities. A Prospectus Supplement is a core document in a financing activity. Since the document explicitly names the attached report as a 'Prospectus Supplement', which directly relates to capital raising, I will classify it as CAP, as it is more specific than the general RPA fallback, although RPA is also plausible under the 'MENU VS MEAL' rule. Given the context of financial filings, a Prospectus Supplement announcement is usually grouped with the financing event itself. I will lean towards CAP as the subject matter is financing, but acknowledge the announcement format. Re-evaluating based strictly on the 'MENU VS MEAL' rule: This is an announcement stating a report is attached. Therefore, RPA is the most appropriate classification for the announcement wrapper.
2020-10-22 English
After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
Regulatory Filings Classification · 1% confidence The document explicitly identifies itself as a "Form 6-K" filed with the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". Form 6-K is the standard filing for a Foreign Private Issuer to report material information that is made public in its home country or required to be reported to a stock exchange outside the U.S. The content is a press release announcing the authorization of a Phase II clinical trial for AllocetraTM in COVID-19 patients, which is material information. Since Form 6-K is a general reporting requirement for foreign private issuers and doesn't fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report), the most appropriate general regulatory filing category is 'Regulatory Filings' (RNS), as it serves as a catch-all for required SEC submissions that aren't the primary periodic reports.
2020-10-13 English
After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
Report Publication Announcement Classification · 1% confidence The document explicitly states it is an 'Immediate Report' filed under Israeli regulations (Securities Authority/Tel Aviv Stock Exchange) and references an attached report on '*6K*'. The document itself is very short (1752 characters) and its primary function is to announce the availability of an external document ('6k13102020_isa.pdf'). This fits the definition of a Report Publication Announcement (RPA), which signals the release of a primary filing, rather than being the primary filing itself (like a 10-K or IR). Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2020-10-13 English
Form 6-K/A- CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K/A filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and six-month periods ended June 30, 2020. Since it provides comprehensive financial data for an interim period (less than a full fiscal year), it is classified as an Interim/Quarterly Report (IR). H1 2020
2020-10-13 English
Form 6-K/A- CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020
Report Publication Announcement Classification · 1% confidence The document explicitly states it is an 'Immediate Report' filed under Israeli regulations ('Regulation 4 of the Securities Regulations'). Crucially, it mentions 'Attached hereto is a report on *6K/A*' and provides a PDF filename. The document length is very short (1759 chars), and its primary function is to announce the availability of an attached report (Form 6-K/A, which is an amendment to a report filed with the SEC, often used by foreign private issuers). According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA).
2020-10-13 English
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a 'Report of Foreign Private Issuer' under the Securities Exchange Act of 1934. The content is a press release announcing positive clinical trial results, which is a typical event requiring disclosure via Form 6-K. Since Form 6-K is not one of the specific codes provided (like 10-K or IR), and it functions as a general regulatory disclosure for foreign issuers, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it represents a mandatory, non-standardized regulatory submission. However, upon reviewing the provided definitions, the document is primarily an 'Earnings Release' (ER) in nature (announcing key financial/clinical results via press release) or potentially an 'Interim Report' (IR) if it contained comprehensive financials, but it is structured as a Form 6-K filing containing a press release. Given the structure (Form 6-K filing containing a press release announcing clinical results), and the fact that 6-K is a general regulatory filing, RNS is a strong candidate. But, the content is a direct announcement of results, similar to an ER. Since the document is a formal SEC filing (6-K) that contains a press release announcing clinical trial results, and 6-K is not explicitly listed, RNS (Regulatory Filings) is the best fit for the *form type* itself, as it is a mandatory filing that doesn't fit 10-K, IR, or ER (which are usually standalone press releases or comprehensive reports). Given the context of SEC filings, RNS serves as the best catch-all for non-standard SEC forms like 6-K.
2020-10-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.